Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
22.50B
Market cap22.50B
Price-Earnings ratio
31.66
Price-Earnings ratio31.66
Dividend yield
Dividend yield
Average volume
1.21M
Average volume1.21M
High today
High today
Low today
Low today
Open price
$141.48
Open price$141.48
Volume
0.00
Volume0.00
52 Week high
$153.06
52 Week high$153.06
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $147.44, with a market capitalization of 22.5B. The stock trades at a price-to-earnings (P/E) ratio of 31.66.

On 2026-01-07, Illumina(ILMN) shares started trading at $141.48, with intraday highs of — and lows of —.

Trading volume for Illumina(ILMN) stock has reached 0, versus its average volume of 1.21M.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

ILMN News

TipRanks 2d
Illumina price target raised to $155 from $142 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Illumina (ILMN) to $155 from $142 and keeps an Outperform rating on the shares. Recovering en...

Simply Wall St 2d
Should Illumina’s Grail Spinoff to Ease Regulatory Pressure Require Action From Investors?

Illumina has recently moved forward with separating its cancer-diagnostics unit Grail, a step aimed at resolving regulatory pressure and sharpening its focus on...

Should Illumina’s Grail Spinoff to Ease Regulatory Pressure Require Action From Investors?

Analyst ratings

43%

of 23 ratings
Buy
39.1%
Hold
43.5%
Sell
17.4%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.